Fig. 2

A-B: In vivo inhibitory effect of anti-NOTCH1 treatment in combination with chemotherapy in PDTALL46 model. Therapeutic effects of COMBO1 and COMBO2 chemotherapy alone or in combination with OMP-52M51 of PDTALL46 outgrowth in NSG mice. Top panels show the percentage of T-ALL cells in the blood of NSG mice at various time points. Bottom panels report the percentage of T-ALL cells in the spleen and bone marrow at sacrifice. (n = 5/6 per group). * P < 0.05; ** P < 0.01; *** P < 0.001. C-D: In vivo inhibitory effect of OMP-52M51 in combination with antimetabolite drugs (COMBO2) in the PDTALL39 and PDTALL-AD4 models. Therapeutic effects of COMBO2 chemotherapy (MTX-6MP-AraC) alone or in combination with OMP-52M51 of PDTALL39 (C) and PDTALL-AD4 (D) outgrowth in NSG mice. Top panels show the percentage of T-ALL cells in the blood of NSG mice at various time points. Bottom panels report the percentage of T-ALL cells in the spleen and bone marrow at sacrifice. Five to six mice per group were used. * P < 0.05; ** P < 0.01; *** P < 0.001. E-G: Anti-NOTCH1 in combination with antimetabolite drugs significantly increases survival in T-ALL PDXs models. Effect of COMBO2 chemotherapy alone or in combination with OMP-52M51 on survival of PDTALL46, PDTALL39 and PDTALL-AD4 injected NSG mice. E-F-G panels show Kaplan-Meier survival curves of PDTALL46, PDTALL39 and PDTALL-AD4 PDXs. Four to seven mice per group were used. Survival curves were compared by log-rank test. H: Visual representation of main results